You just read:

Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis

News provided by

Boston Biomedical, Inc.

Jul 01, 2019, 23:45 ET